Oppenheimer & Co’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Oppenheimer & Co’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,048	Closed	-$210K	–	1585
2021 Q2	$210K	Buy	+4,048	New	+$203K	﹤0.01%	1405
2020 Q4	–	Sell	-4,631	Closed	-$201K	–	1415
2020 Q3	$201K	Sell	4,631 -390	-8%	-$17.1K	0.01%	1159
2020 Q2	$216K	Buy	+5,021	New	+$208K	0.01%	1090
2018 Q4	–	Sell	-4,114	Closed	-$200K	–	1375
2018 Q3	$200K	Sell	4,114 -1,866	-31%	-$88.4K	0.01%	1232
2018 Q2	$257K	Sell	5,980 -142	-2%	-$5.96K	0.01%	1123
2018 Q1	$256K	Sell	6,122 -3,356	-35%	-$146K	0.01%	1122
2017 Q4	$413K	Sell	9,478 -97	-1%	-$4.13K	0.01%	935
2017 Q3	$407K	Buy	9,575 +1,412	+17%	+$59.9K	0.01%	924
2017 Q2	$351K	Buy	8,163 +745	+10%	+$31.4K	0.01%	967
2017 Q1	$310K	Buy	7,418 +1,401	+23%	+$57.1K	0.01%	985
2016 Q4	$235K	Buy	6,017 +1,433	+31%	+$58.3K	0.01%	1097
2016 Q3	$203K	Buy	+4,584	New	+$208K	0.01%	1138
2016 Q1	–	Sell	-4,848	Closed	-$248K	–	1331
2015 Q4	$248K	Sell	4,848 -2,928	-38%	-$149K	0.01%	1030
2015 Q3	$364K	Buy	7,776 +3,336	+75%	+$201K	0.01%	924
2015 Q2	$276K	Buy	4,440 +48	+1%	+$2.99K	0.01%	1129
2015 Q1	$271K	Sell	4,392 -354	-7%	-$21K	0.01%	1142
2014 Q4	$256K	Sell	4,746 -454	-9%	-$24.8K	0.01%	1097
2014 Q3	$275K	Buy	5,200 +850	+20%	+$43.2K	0.01%	1110
2014 Q2	$226K	Sell	4,350 -672	-13%	-$32.4K	0.01%	1199
2014 Q1	$235K	Sell	5,022 -60	-1%	-$2.83K	0.01%	1159
2013 Q4	$224K	Buy	+5,082	New	+$212K	0.01%	1159

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Oppenheimer & Co's XPH Position: Q3 2021 in Review

Oppenheimer & Co sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2021, closing a stake of 4,048 shares — an estimated $210K sold.

Oppenheimer & Co first reported a position in XPH in Q4 2013 and held it in 21 quarters. The position peaked at $413K in Q4 2017. 78 funds tracked by Wall St. Rank hold XPH as of Q3 2021.

Oppenheimer & Co reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2021 after selling out during the quarter.
Oppenheimer & Co sold 4,048 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2021, an estimated $210K.
Oppenheimer & Co first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2013 and held it in 21 quarters.
Oppenheimer & Co's State Street SPDR S&P Pharmaceuticals ETF position peaked at $413K in Q4 2017.
78 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.